ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
PharmaEssentia
The Director, Patient Access leads PharmaEssentia's patient access function, overseeing strategy, operations, vendor governance, and performance of programs such as hubs, specialty pharmacy partnerships, and affordability initiatives. This senior leader manages a team of Patient Support Specialists, drives continuous improvement, and collaborates cross‑functionally to ensure compliance, data integrity, and a positive experience for patients and providers.
Headquarters
Burlington, Massachusetts, United States
Company Size
201-500 employees
Founded
2003
PharmaEssentia is a Taiwan-based global biopharmaceutical company focused on researching, developing, and commercializing best-in-class therapies for blood disorders and other serious diseases. Its portfolio includes Ropeginterferon alfa‑2b (marketed as Besremi) for polycythemia vera and other myeloproliferative neoplasms, and the company conducts clinical trials, medical affairs, and manufacturing activities worldwide. PharmaEssentia provides resources for patients and healthcare professionals and emphasizes innovation in protein engineering and biologics production. It aims to bring effective, scientifically driven treatments to patients through robust R&D and global partnerships.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for PharmaEssentia.